ketamine has been researched along with Parkinson Disease in 15 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life." | 2.58 | NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. ( Bashmi, L; Danovitch, I; IsHak, WW; Jimenez, J; Olcott, W; Vanle, B, 2018) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "(R)-ketamine has greater and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression." | 1.56 | MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. ( Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y, 2020) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pottenger, AE | 1 |
| Bartlett, MJ | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Morrison, HW | 1 |
| Erdman, HB | 1 |
| Kornilov, E | 1 |
| Kahana, E | 1 |
| Zarchi, O | 1 |
| Reiner, J | 1 |
| Socher, A | 1 |
| Strauss, I | 1 |
| Firman, S | 1 |
| Israel, Z | 1 |
| Bergman, H | 1 |
| Tamir, I | 1 |
| Fujita, A | 1 |
| Fujita, Y | 1 |
| Pu, Y | 1 |
| Chang, L | 1 |
| Hashimoto, K | 1 |
| Vecchia, DD | 2 |
| Kanazawa, LKS | 2 |
| Wendler, E | 2 |
| Hocayen, PAS | 1 |
| Vital, MABF | 2 |
| Takahashi, RN | 1 |
| Da Cunha, C | 2 |
| Miyoshi, E | 2 |
| Andreatini, R | 2 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Vanle, B | 1 |
| Olcott, W | 1 |
| Jimenez, J | 1 |
| Bashmi, L | 1 |
| Danovitch, I | 1 |
| IsHak, WW | 1 |
| Lerner, RP | 1 |
| Bimpisidis, Z | 2 |
| Agorastos, S | 1 |
| Scherrer, S | 1 |
| Dewey, SL | 1 |
| Cenci, MA | 2 |
| Eidelberg, D | 1 |
| Öberg, CM | 1 |
| Maslava, N | 1 |
| Lundblad, C | 1 |
| Wright, JJ | 1 |
| Goodnight, PD | 1 |
| McEvoy, MD | 1 |
| Pan, J | 1 |
| Xiao, Q | 1 |
| Sheng, CY | 1 |
| Hong, Z | 1 |
| Yang, HQ | 1 |
| Wang, G | 1 |
| Ding, JQ | 1 |
| Chen, SD | 1 |
| Lettieri, C | 1 |
| Rinaldo, S | 1 |
| Devigili, G | 1 |
| Pauletto, G | 1 |
| Verriello, L | 1 |
| Budai, R | 1 |
| Fadiga, L | 1 |
| Oliynyk, A | 1 |
| Mondani, M | 1 |
| D'Auria, S | 1 |
| Skrap, M | 1 |
| Eleopra, R | 1 |
| Ferro, MM | 1 |
| Angelucci, ME | 1 |
| Anselmo-Franci, JA | 1 |
| Canteras, NS | 1 |
| Hetherington, A | 1 |
| Rosenblatt, RM | 1 |
| Hershey, T | 1 |
| Black, KJ | 1 |
| Carl, JL | 1 |
| Perlmutter, JS | 1 |
| Carlsson, M | 1 |
| Svensson, A | 1 |
| Carlsson, A | 1 |
1 review available for ketamine and Parkinson Disease
| Article | Year |
|---|---|
NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Depression; Excitatory Amino Acid Antagonists; Humans; | 2018 |
14 other studies available for ketamine and Parkinson Disease
| Article | Year |
|---|---|
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, A | 2021 |
Asleep DBS under ketamine sedation: Proof of concept.
Topics: Anesthesia, General; Brain Neoplasms; Deep Brain Stimulation; Humans; Ketamine; Microelectrodes; Par | 2022 |
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; | 2020 |
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Fema | 2016 |
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskines | 2017 |
The utility of ketamine for the preoperative management of a patient with Parkinson's disease.
Topics: Anesthesia, Inhalation; Anesthetics, Dissociative; Female; Humans; Intubation, Intratracheal; Ketami | 2009 |
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Blotting, Western; Cell Nucle | 2009 |
Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients.
Topics: Aged; Anesthesia, General; Anesthesia, Local; Deep Brain Stimulation; Female; Humans; Ketamine; Male | 2012 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
Ketamine and paralysis agitans.
Topics: Aged; Anesthesia, Intravenous; Humans; Ketamine; Male; Parkinson Disease | 1980 |
Dopa-induced blood flow responses in nonhuman primates.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Arousal; Carbidopa; Cerebrovascular Circul | 2000 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilp | 1991 |